Please use this identifier to cite or link to this item:
Title: Recent advances and new strategies on leishmaniasis treatment.
Authors: Roatt, Bruno Mendes
Cardoso, Jamille Mirelle de Oliveira
Brito, Rory Cristiane Fortes de
Vital, Wendel Coura
Soares, Rodrigo Dian de Oliveira Aguiar
Reis, Alexandre Barbosa
Keywords: Conventional chemotherapy
Multi-drug therapy
Drug repurposing
Issue Date: 2020
Citation: ROATT, B. M. et al. Recent advances and new strategies on leishmaniasis treatment. Applied Microbiology and Biotechnology, v. 104, p. 8965-8977, 2020. Disponível em: <>. Acesso em: 10 jun. 2021.
Abstract: Leishmaniasis is one of the most important tropical neglected diseases according to the World Health Organization. Even after more than a century, we still have few drugs for the disease therapy and their great toxicity and side effects put in check the treatment control program around the world. Moreover, the emergence of strains resistant to conventional drugs, co-infections such as HIV/Leishmania spp., the small therapeutic arsenal (pentavalent antimonials, amphotericin B and formulations, and miltefosine), and the low investment for the discovery/development of new drugs force researchers and world health agencies to seek new strategies to combat and control this important neglected disease. In this context, the aim of this review is to summarize new advances and new strategies used on leishmaniasis therapy addressing alternative and innovative treatment paths such as physical and local/topical therapies, combination or multi-drug uses, immunomodulation, drug repurposing, and the nanotechnology-based drug delivery systems.
ISSN: 1432-0614
Appears in Collections:DEACL - Artigos publicados em periódicos

Files in This Item:
File Description SizeFormat 
  Restricted Access
519,64 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.